Connect Biopharma Holdings Limited
CNTB
$2.45
-$0.23-8.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -98.69% | -99.80% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -98.69% | -99.80% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -98.69% | -99.80% | -- | -- |
| SG&A Expenses | 3.99% | 32.83% | 6.26% | 21.26% | 2.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.49% | 33.38% | 48.53% | -9.39% | -42.18% |
| Operating Income | -61.41% | -46.75% | -189.22% | 9.39% | 46.09% |
| Income Before Tax | -71.39% | -33.70% | -186.33% | -17.95% | 44.26% |
| Income Tax Expenses | -74.53% | 7.02% | 83.33% | 80.00% | 278.57% |
| Earnings from Continuing Operations | -69.65% | -33.58% | -186.88% | -18.16% | 43.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.65% | -33.58% | -186.88% | -18.16% | 43.69% |
| EBIT | -61.41% | -46.75% | -189.22% | 9.39% | 46.09% |
| EBITDA | -62.19% | -47.41% | -187.14% | 9.58% | 46.45% |
| EPS Basic | -67.39% | -32.49% | -186.39% | -17.62% | 43.92% |
| Normalized Basic EPS | -69.11% | -54.33% | -178.46% | -17.40% | 44.50% |
| EPS Diluted | -67.39% | -32.49% | -186.39% | -17.62% | 44.27% |
| Normalized Diluted EPS | -69.11% | -54.33% | -179.19% | -17.40% | 44.50% |
| Average Basic Shares Outstanding | 1.38% | 0.84% | 0.57% | 0.45% | 0.41% |
| Average Diluted Shares Outstanding | 1.38% | 0.84% | -0.38% | 0.45% | 0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |